General information | |
ACovPid: | ACoVP100393 |
Trivial Name: | M-wt |
Amino Acids Sequence: | KYEQYIKWPWYVWLGF |
Length: | 16 |
C-Terminal Modification: | None |
N-Terminal Modification: | None |
Chemical Modification: | None |
Peptide Source: | Severe acute respiratory syndrome coronavirus (SARS-CoV) : 694009 |
Source Description: | |
Against Virus: | Severe acute respiratory syndrome coronavirus (SARS-CoV) : 694009 |
Inhibition Value Type: | IC50 |
Inhibitory Effect: | 26 |
Inhibitory Unit: | µM |
Target Domain Name: | |
Assay: | in Vitro assay |
Assay Description: | The ability of MPER in both complementary interaction (with IFP) and self-interaction raised the possibility that MPER-derived peptides could serve as viral entry inhibitors. In principle, both MPER and IFP are exposed during viral entry, and their association with a MPERderived peptide could inhibit the progression of viral entry and infection. For safety reasons, the inhibitory activity of M-wt peptide was tested in neutralization assays using avian infectious bronchitis virus (IBV), instead of SARS-CoV. IBV contains the same MPER sequence and undergoes a fusion process synonymous to that of SARS-CoV. Specifically, the assay was conducted on recombinant IBV-Luc, which contains a firefly luciferase gene integrated at its ORF3a3b. Successful viral entry and subsequent replication of IBV-Luc were assessed by intracellular luciferase activity. The MPER peptide derived from IBV, M-ibv (LKTYIKWPWYVWLAIAF), was tested in parallel. Increasing concentrations of synthetic MPER peptides (0, 12, 25, and 50 µM) were mixed with IBV-Luc for 1 h at 37 °C and applied to Vero E6 cells seeded in a 96-well plate at 1 PFU. The peptide/virus mixture was removed 1 h postinfection. Cells were lysed 20 h postinfection, and luciferase activity was measured. |
Anti-CoV activity in vivo: | |
Reference: | 25668103 |
Comment: | |
3D structure: | |
Structure Experiment Verified: | NO |
Similar Peptides: | ACoVP100218   ACoVP100228   ACoVP100242   ACoVP100246   ACoVP100250 |